Results 81 to 90 of about 298,421 (156)

Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates

open access: yes, 2010
The skin is the second most frequently affected organ system in lupus erythematosus. Although only very rarely life threatening — an example is lupus erythematosus-associated toxic epidermal necrolysis — skin disease contributes disproportionally to ...
RD Sontheimer, G. Obermoser, B. Zelger
core   +1 more source

Cutaneous lupus erythematosus

open access: yes, 2016
Cutaneous lupus erythematosus (LE) is an autoimmune disease. The most common clinical forms are acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE) and discoid LE (DLE). Cutaneous LE, mainly ACLE, can be the first sign of systemic LE (SLE).
Sandreva, Tatjana   +2 more
core   +1 more source

Facial Eruption Mimicking Subacute Cutaneous Lupus Erythematosus: A Diagnostic Challenge

open access: yes
Facial erythematous and scaly dermatoses may represent a diagnostic challenge because of their varied clinical presentations and overlapping features.
Y. Zemmez   +5 more
core   +1 more source

Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study [PDF]

open access: yes, 2013
We determined whether any individual cancers are increased or decreased in a cohort of 595 patients with systemic lupus erythematosus (SLE) followed for up to 32 years at the University College London Hospitals Lupus Clinic, looking for any associated ...
Kenu, E, Dey, D, Isenberg, DA
core  

Apoptosis in chronic cutaneous lupus erythematosus, discoid lupus, and lupus profundus [PDF]

open access: yes, 2015
: Introduction: Lupus erythematosus is a multisystemic disease that is characterized by autoantibody production and immune complex deposition in such tissues as the mucosa, joints, the central nervous system, and skin.
Felipe de Jesús, Torres del Muro   +7 more
core   +1 more source

Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases

open access: yesRevista da Sociedade Portuguesa de Dermatologia e Venereologia
Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant ...
Gilberto P. da Rosa   +6 more
doaj  

SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS WITH PSEUDO-PORPHYRIA AND VITILIGO

open access: yes, 2003
Sub acute Cutaneous Lupus Erythematosus (SCLE) is a distinct subset of Lupus Erythematosus. It can present as non scarring psoriasiform or annular polycyclic lesions.
H Sripathi, M Dahal, A Basu
core   +1 more source

The combined role of clinical, reflectance confocal microscopy and dermoscopy applied to chronic discoid cutaneous lupus and subacutus lupus erythematosus: a case series and literature review

open access: yes, 2020
Main subtypes of cutaneous lupus erythematosus are represented by acute, subacute cutaneous, intermittent and chronic cutaneous lupus erythematosus. Discoid lupus erythematosus represents the most common phenotype of chronic cutaneous lupus erythematosus.
Botti, Elisabetta   +21 more
core   +1 more source

Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. [PDF]

open access: yes, 2011
The long pentraxin PTX3 has multiple roles in innate immunity. For example, PTX3 regulates C1q binding to pathogens and dead cells and regulates their uptake by phagocytes. It also inhibits P-selectin-mediated recruitment of leukocytes.
Mantovani Alberto   +32 more
core   +1 more source

Nitrendipine-induced subacute cutaneous lupus erythematosus

open access: yes, 2003
A 66-year-old man presented with widespread annular and bullous subacute cutaneous lupus erythematosus (SCLE), developed after starting treatment for hypertension with the calcium channel blocker nitrendipine.
Caputo, Ruggero   +4 more
core  

Home - About - Disclaimer - Privacy